Multiplexed epigenome editing for enhanced CAR T cell potency
A novel genotoxic-free multiplexed epigenome editing strategy to enhance CAR T cell potency by inhibiting immune checkpoint receptors, improving their efficiency in tumor eradication without the risks of traditional gene editing.
Overview
This innovative research proposes a genotoxic-free multiplexed epigenome editing strategy to enhance the potency of CAR T cells. By targeting key immune checkpoint receptors such as PD1, LAG3, CTLA4, and TIM3, this approach seeks to reduce CAR T cell exhaustion and improve anti-tumor efficacy. The solution leverages designer epigenome modifiers (DEMs) to inhibit these checkpoints, avoiding the risks associated with traditional gene editing methods like genotoxicity.
Technical specifications
Key features:
- Utilizes designer epigenome modifiers (DEMs) to repress expression of checkpoint genes without DNA breaks or permanent alterations
- Targets immune checkpoint receptors PD1, LAG3, CTLA4, and TIM3 to reduce CAR T cell exhaustion
- Compatible with cost-effective, large-scale manufacturing protocols for CAR T cell production
- Provides a safer alternative to genome editing by avoiding genotoxic and immune-related adverse events
Technology readiness level
This technology is at a Technology Readiness Level (TRL) 3, indicating that it is in the early stages of experimental proof of concept. The research is focused on validating the multiplexed epigenome editing method to generate improved CAR T cells with enhanced tumor-fighting capabilities.
About Universitätsklinikum Freiburg
Universitätsklinikum Freiburg is the academic medical center in Freiburg, Germany, and the teaching hospital of the University of Freiburg, uniting patient care and research. Integrated clinical–research infrastructure supports collaborations: centralized study design/coordination, early-phase trials, hospital biobanks, GMP-compliant cell processing and investigational product services, and shared core facilities. Its Upper Rhine location links to the tri-national BioValley and cross-border hospital partnerships, providing rapid access to suppliers, talent, and trial sites across Germany, France, and Switzerland. Research is backed by competitive funding from the German Research Foundation (DFG), the Federal Ministry of Education and Research (BMBF), and the EU. Technology transfer is handled by the university’s TTO with Campus Technologies Freiburg for IP, licensing, and industry agreements.
delivered to your inbox.